Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending January 13, 2019
Residents get less parental leave than faculty physicians, Magudia K et al. JAMA. 2018 Dec 11;320[22)]:2372-4; Varda B et al. JAMA. 2018 Dec 11;320[22]:2374-7
Open enrollment surge doubles plans selected , Centers for Medicare & Medicaid Services
Health care spending slowed but fewer insured, Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085
Most physicians do not use telemedicine, Kane C et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05077
Physician burnout linked to EHRs, Gardner R et al. J Am Med Inform Assoc. doi: 10.1093/jamia/ocy145.
Must reads for theWeek ending January 6, 2019
Apixaban tied to lower VTE rate, higher bleeding risk in cancer, Carrier M et al. N Engl J Med. 2018 Dec 4. doi: 10.1056/NEJMoa1814468
Must reads for theWeek ending December 30, 2018
Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9
Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0
Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0
Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4
Emapalumab for primary hemophagocytic lymphohistiocytosis, Locatelli F et al. ASH 2018; Abstract LBA-6
Must reads for theWeek ending December 23, 2018
Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4
Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123
Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3
Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900
Must reads for theWeek ending December 16, 2018
Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8
Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.
Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1
Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491
Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5